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Psoriasis is a chronic inﬂammatory skin disease characterized by abnormal epidermal proliferation. Several stud-
ies have shown that skin-inﬁltrating activated T cells and cytokines play a pivotal role during the initiation and
maintenance of the disease. Interferon (IFN)-a plays an important role in host defense against infections, but recent
data have also implicated IFN-a in psoriasis. Thus, IFN-a induces or aggravates psoriasis in some patients, and
mice lacking a transcriptional attenuator of IFN-a/b signaling spontaneously develop a psoriasis-like inﬂammatory
skin disease characterized by CD8þ -inﬁltrating T cells. In this study, we therefore investigate IFN-a signaling in T
cells isolated from involved skin of psoriatic patients. We show that psoriatic T cells have increased and prolonged
responses to IFN-a, on the level of signal transducers and activators of transcription (STAT) activation, compared
with inﬁltrating T cells from skin of non-psoriatic donors. Functionally, the increased IFN-a signaling leads to an
increased binding of STAT4 to the IFN-c promotor, IFN-c production, and inhibition of T cell growth. In contrast, to
STAT responses to other cytokines were not changed in psoriasis. In conclusion, we provide evidence that
psoriatic T cells have an increased sensitivity to IFN-a. Thus, our data suggest that increased IFN-a signaling is
involved in the pathogenesis of psoriasis.
Key words: cytokines/inflammation/signal transduction/skin/T lymphocytes
J Invest Dermatol 125:936 –944, 2005
Psoriasis is a chronic inflammatory skin disease affecting
around 2% of the global population. It is characterized by T-
lymphocyte infiltration and hyperproliferation of the epider-
mis in involved areas of the skin (Lew et al, 2004). Of the
infiltrating lymphocytes, both CD4þ Th1 cells and CD8þ
cytotoxic T cells have been reported to play a pathogenic
role (Austin et al, 1999; Friedrich et al, 2000), but also cells
expressing NK and NK-T cell markers have recently been
found in psoriatic plaques (Nickoloff et al, 2000; Cameron
et al, 2002). By their production of Th1 and pro-inflamma-
tory cytokines, especially the type II interferon (IFN), IFN-g,
and growth factors, the T cells contribute to the activation
and hyperproliferation of keratinocytes (Nickoloff, 1987; Ba-
adsgaard et al, 1990; Fierlbeck et al, 1990; Strange et al,
1993; Uyemura et al, 1993; Schlaak et al, 1994; Szabo et al,
1998; Bonifati and Ameglio, 1999). Indeed, it is now well
established that skin-infiltrating activated T cells and the
local overexpression of pro-inflammatory cytokines play a
pivotal role during initiation and maintenance of the disease
(White et al, 1972; Baker et al, 1984; Gottlieb et al, 1995;
Wrone-Smith and Nickoloff, 1996; Lew et al, 2004).
The type I IFNs, IFN-a/b, are believed to play an impor-
tant role in host defense against viral and bacterial infec-
tions and are involved in many immunoregulatory processes
(Brassard et al, 2002). Because of its antiviral and antipro-
liferative activity on many cell types, IFN-a has proved to
be useful for treating several clinical conditions, including
chronic viral hepatitis and chronic myeloproliferative and
lymphoproliferative disorders (Brassard et al, 2002). IFN-a
transduces signals directly to the nucleus through rapid
activation of the Janus kinase (JAK)/signal transducers and
activators of transcription (STAT) signaling pathway. By
binding of IFN-a to its high-affinity receptor, receptor-asso-
ciated JAKs become activated by tyrosine phosphorylation.
Once activated, the JAK phosphorylate key tyrosine resi-
dues in the cytoplasmic receptor tails, creating docking
sites for STAT transcription factors. Upon tyrosine phos-
phorylation by JAKs, the recruited STATs dimerize and
translocate to the nucleus where they induce transcription
of cytokine-inducible genes (Kisseleva et al, 2002). IFN-a
induces activation of Tyrosine kinase 2/JAK1 bound to the
IFN-a receptor (IFNAR)-1/IFNAR-2, respectively (Kotenko
and Pestka, 2000). IFN-a stimulation thereby leads to ac-
tivation of several STAT proteins, including STAT1, STAT2,
and STAT4. Once activated, STAT1/STAT2 heterodimers to-
gether with interferon regulatory factor (IRF)-9, thereby con-
stituting the IFN-stimulated gene factor 3 complex, bind to
the IFN-stimulated response element in the promotor region
The work described in this manuscript was performed at the
Institute of Medical Microbiology and Immunology, University of
Copenhagen, Denmark.
Abbreviations: 7-AAD, 7-amino-actinomycin D; ERK, extracellular-
signal-regulated kinase; FACS, fluorescence-activated cell sorting;
IFN, interferon; IFNAR, IFN-a-receptor; IL, interleukins; IRF, inter-
feron regulatory factor; JAK, Janus kinase; pAb, polyclonal Ab;
PBL, peripheral blood lymphocytes; PY-STAT, tyrosine-phosphory-
lated STAT; STAT, signal transducers and activators of transcription
Copyright r 2005 by The Society for Investigative Dermatology, Inc.
936
of IFN-a-inducible genes, thereby assisting in their tran-
scriptional activation (Kotenko and Pestka, 2000). STAT4
has been demonstrated to bind to the promotor of IFN-g
gene, and assists in the regulation of its transcription (Xu
et al, 1996).
Compared with the well-studied role of IFN-g, little is
known about the eventual role of IFN-a in the pathogenesis
of psoriasis. Nevertheless, several observations suggest
that IFN-a might be involved. The use of IFN-a as a ther-
apeutic agent in some susceptible individuals has led to the
development or aggravation of psoriasis (Conlon et al, 1990;
Funk et al, 1991; Pauluzzi et al, 1993; Brenard, 1997; Cal-
vino et al, 1999; Erkek et al, 2000), and the association
between psoriasis and chronic viral infections has been
reported (Yamamoto et al, 1995; Erkek et al, 2000). Fur-
thermore, the immunoregulatory actions of IFN-a include
upregulation of type 1 immune responses through the direct
or indirect enhancement of differentiation and activation of
both CD4þ Th1 cells and CD8þ Tc1 cells, and NK cell ac-
tivation (Ortaldo et al, 1980; Brinkmann et al, 1993; Tough
et al, 1996; Brassard et al, 2002). Finally, mice lacking
a transcriptional attenuator of IFN-a/b signaling, the IRF-2
protein (IRF-2/ mice), have recently been shown to de-
velop psoriasis-like inflammatory skin disease, which was
dependent on CD8þ -infiltrating T cells, and was caused by
uncontrolled IFN-a/b signaling (Hida et al, 2000). Given the
crucial role of T cells in the onset and maintenance of the
disease, this study was therefore undertaken to investigate
IFN-a signaling in T cells isolated from involved skin of
psoriatic patients. We show that psoriatic T cells have in-
creased and prolonged responses to IFN-a, on the level of
STAT activation, compared with infiltrating T cells from skin
of non-psoriatic donors. Functionally, the increased IFN-a
signaling leads to an increased binding of STAT4 to the IFN-
g promotor, IFN-g production, and inhibition of T cell growth.
In contrast to the abnormal IFN-a response, STAT respons-
es to other cytokines were not changed in psoriasis. We
hereby provide evidence that psoriatic T cells have an in-
creased sensitivity to IFN-a. Our data thus suggest that in-
creased IFN-a signaling is involved in the pathogenesis of
psoriasis.
Results
Psoriatic T cells show increased IFN-a-induced signa-
ling In order to study IFN-a signaling in psoriatic T cells, we
first examined the IFN-a-induced STAT activation in a CD8þ
T cell line, Psor-2, isolated from involved skin of a psoriatic
patient, and compared it with the activation in a skin-infil-
trating CD8þ control T cell line, Control-1, from a non-
psoriatic donor. As shown in Fig 1A, IFN-a induced a strong
tyrosine phosphorylation of STAT1, STAT2, and STAT3 in
Psor-2 cells in a concentration-dependent manner. Inter-
estingly, the IFN-a-induced activation of STAT1 and STAT2,
and to a lesser extent STAT3, was significantly stronger in
Psor-2 cells than in Control-1 cells, even though a compa-
rable amount of STAT and extracellular-signal-regulated kin-
ase (ERK) protein was present in each lane. Essentially,
similar responses were obtained when comparing psoriatic
T cells with CD8þ -infiltrating skin cells from other donors
without psoriasis (Fig 1B, data not shown). Interestingly, the
activation of STAT4 was also increased in psoriatic T cells
(Fig 1B). In contrast to IFN-a, interleukin (IL)-2-induced ty-
rosine phosphorylation of STAT5 was not significantly in-
creased (Fig 1C), suggesting that psoriatic T cells did not
have an increased response to cytokines in general. In hu-
man psoriatic keratinocytes, STAT proteins were found to
be constitutively active (van der Fits et al, 2004; Sano et al,
2005). In contrast, STAT proteins were not constitutively
activated in psoriatic T cells (Figs 1 and 2, data not shown).
Prolonged response to IFN-a in psoriatic T cells To in-
vestigate the IFN-a response over time, a kinetic study was
performed, where Psor-2 cells were stimulated with IFN-a
for different periods of time and compared with the re-
sponse in Control-2 cells. As shown in Fig 2A, Psor-2 cells
responded to IFN-a for longer periods of time, suggesting
that psoriatic T cells from this patient also have prolonged
Figure1
Increased interferon (IFN)-a-induced signaling in psoriatic T cells.
(A–C) CD8þ psoriatic T cells, Psor-2, and CD8þ skin-infiltrating control
T cells from two different non-psoriatic donors, Control-1 and Control-
2, were stimulated with IFN-a or interleukin (IL)-2 as indicated for 10
min and lysed. Total cell lysates were subjected to western blotting
using an Ab recognizing tyrosine-phosphorylated signal transducers
and activators of transcription (PY-STAT1) or PY-STAT5. The blots were
subsequently stripped and reprobed with the indicated Abs (P2, Psor-2;
C2, Control-2).
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responses to IFN-a. Essentially identical results were ob-
tained in seven independent experiments (Fig 2B, data not
shown).
To address whether the difference in IFN sensitivity was
because of different levels of IFNAR expression, we com-
pared IFNAR levels in total lysates and on the surface of
psoriatic T cells and control T cells. Differences in IFN sen-
sitivity, however, did not seem to be mediated by an in-
creased amount of the IFNAR, as a comparable amount of
the IFNAR-1 was found in psoriatic and control T cells (Fig
2C). Similar results were obtained when measuring the sur-
face expression of IFNAR-1 by fluorescence-activated cell
sorting (FACS) analysis (Fig 2D). Having found that Psor-2
cells were both more sensitive and had prolonged respons-
es to IFN-a, we wished to address whether this was also
true for psoriatic T cells from other patients. We therefore
analyzed the IFN-a response in psoriatic T cells isolated
from involved skin of three additional patients: Psor-3, from
one patient, Psor-19 and -18 from another patient, and
Psor-17 and -16 from a third patient. All psoriatic T cells
clearly showed increased IFN-a-mediated activation of
STAT1, STAT2, STAT3, and STAT4 (Fig 3A–C, data not
shown). Again, this correlated with a comparable surface
expression of the IFNAR measured by FACS analysis (data
not shown). The apparent differences in STAT activation as
judged from band intensities between individual experi-
ments are caused by differences in exposure time during
enhanced chemiluminiscence (ECL) development. This is
illustrated in Fig 3B and C where different exposures of
STAT1 and STAT2 are shown. Although an increase in ex-
posure time manifests itself as an increase in band intensi-
ties, it has no influence on the relative difference in IFN-a
responses between patients and controls. Thus, the in-
creased sensitivity to IFN-a in psoriasis is seen at all ex-
posure times (Fig 3B and C). Similar results were also
obtained in identical, but independent experiments (Fig 4A,
data not shown). As shown recently by Kohlmann et al
(2004), expansion of T cell lines in culture might change the
characteristics of the cells. Yet, an increased sensitivity to
IFN-a is seen in psoriatic T cells from the same patient cul-
tured for a short (o2 wk) and longer (>1 mo) period of time
(Fig 4A vs B). In conclusion, these findings support the
above observations, that psoriatic T cells have increased
sensitivity to IFN-a.
Peripheral blood lymphocytes (PBL) from psoriasis pa-
tients show increased IFN-a-induced signaling In order
to address whether an increased sensitivity to IFN-a was a
unique feature of lesional T cells or a general phenomenon
of psoriatic T cells, we compared IFN-a responses in PBL
obtained from psoriasis patients and healthy donors (see
‘‘Materials and Methods’’). As shown in Fig 5, an enhanced
STAT1, STAT2, and STAT4 (and to some extent STAT3) ac-
tivation was observed in PBL from psoriasis patients when
compared with healthy donors. Similar amounts of proteins
had been loaded in all lanes as illustrated by the band in-
tensities for ERK1/2. The amount of total STAT proteins,
however, was also elevated in PBL when compared with
healthy donors, indicating that peripheral T cells from pso-
riasis patients also differ from healthy controls.
Increased STAT–DNA binding to the IFN-c promotor To
address whether the increased IFN-a-induced STAT activa-
tion had a functional effect on downstream events, we
examined the STAT–DNA binding and cytokine produc-
tion. Activation of STAT4 triggers binding of STAT4 to the
Figure 2
Prolonged response to interferon (IFN)-a in psoriatic T cells. (A–C) Psor-2 and Control-2 cells were stimulated with IFN-a (10,000 U per mL) for
the indicated periods of time. Total cell lysates were subjected to western blotting using the indicated Abs. (D) Psor-2 and Control-2 cells were
examined by fluorescence-activated cell sorting analysis using the indicated Abs (fluorescence intensity from iso-type control-Ab is represented by
a full line).
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promotor of the IFN-g gene (Xu et al, 1996) and STAT4-
dependent expression of IFN-g (Rogge et al, 1998). Ac-
cordingly, Psor-2 and Control-2 cells were stimulated with
IFN-a prior to affinity purification with a biotinylated
oligonucleotide probe representing a STAT4-binding se-
quence for the IFN-g promotor. As shown in Fig 6A and B,
IFN-a induced an increased binding of STAT4 to the IFN-g
promotor in Psor-2 cells when compared with non-psoriatic
skin T cells. Likewise, IFN-a induced an enhanced IFN-g
production in Psor-2 cells when compared with the non-
psoriatic skin T cells (Fig 6C).
IFN-a signaling correlates with increased inhibition of T
cell growth As another functional study of increased IFN-a
Figure 3
Prolonged response to interferon (IFN)-a in psoriatic T cells from
other patients. Psoriatic T cells, Psor-3 (A), Psor-19 (B), Psor-17 (C),
and Control-2 cells were stimulated with IFN-a (10,000 U per mL) for
the indicated periods of time. Total cell lysates were subjected to
western blotting using the indicated Abs.
Figure4
Prolonged response to interferon (IFN)-a in psoriatic T cells cul-
tured for short and longer periods of time. Psoriatic T cell lines from
the same patient, Psor-19 and -18, were subjected to short-term cul-
ture (A) or long-term culture (B). Psoriatic T cells and Control-2 cells
were subsequently stimulated with IFN-a (10,000 U per mL) for the
indicated periods of time. Total cell lysates were subjected to western
blotting using the indicated Abs.
Figure5
Peripheral blood lymphocytes (PBL) from psoriasis patients show
increased interferon (IFN)-a-induced signaling. PBL from psoriasis
patients and healthy control donors were stimulated with IFN-a as in-
dicated for 10 min and lysed. Total cell lysates were subjected to
western blotting using the indicated Abs.
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response in psoriatic T cells, we looked at the ability of IFN-
a to induce growth arrest in human T cells (Balkwill and
Oliver, 1977; Brassard et al, 2002). Psor-2 cells and Control-
2 cells were incubated with IFN-a in culture medium with IL-
2 for 24, 48, 72, and 96 h. As shown in Fig 7A, IFN-a clearly
inhibited IL-2-mediated growth after 96 h in a concentra-
tion-dependent manner. The inhibition was also time de-
pendent (data not shown), but essentially, the inhibition was
strongest in Psor-2 cells compared with Control-2 cells at all
time points (Fig 7A, data not shown). Similar results were
obtained on comparing Psor-2 cells with T cells isolated
from the blood of healthy donors (data not shown). This
effect was especially significant at lower concentrations of
IFN-a, which was in agreement with the signaling data. In
some T cells, the growth inhibition is accompanied with an
increase in apoptosis. But IFN-a did not induce apoptosis in
psoriasis or control skin T cells after 24 h (Fig 7B) or at later
time points (data not shown).
Discussion
In this study, we demonstrate that T cells isolated from in-
volved skin and blood of psoriatic patients have increased
responsiveness to IFN-a. Thus, IFN-a-induced signaling is
increased and prolonged on the level of STAT activation,
compared with infiltrating T cells from skin of non-psoriatic
donors. The increased IFN-a signaling functionally leads to
Figure 6
Increased signal transducers and activators of transcription
(STAT)–DNA binding to the interferon (IFN)-c promotor and IFN-c
production in psoriatic T cells. (A) Psor-2 and Control-2 cells were
stimulated with IFN-a as indicated for 10 min, lysed, and STAT proteins
were affinity purified with a STAT-binding biotinylated double-stranded
oligonucleotide probe, Bio-IFN-g, and analyzed by western blotting
using an Ab against STAT4. Total cell lysates from stimulated cells were
also subjected to western blotting using the indicated Abs. (B) Band
intensities from (A, upper row), were quantified and calculated relative
to, or subtracted, the value from non-stimulated cells. (C) Psor-2 and
Control-2 cells were cultured with IFN-a (10,000 U per mL) for 24 h.
Supernatants were then tested for IFN-g production by ELISA. The IFN-
a-induced IFN-g release is depicted as change in percent of the IFN-g
release detected in cells incubated without IFN-a.
Figure7
Increased growth inhibition in psoriatic T cells. (A) Psor-2 and Con-
trol-2 cells were cultured with interferon (IFN)-a as indicated in culture
medium with IL-2 (1000 U per mL) for 96 h. Cell cultures were sub-
sequently subjected to [3H]thymidine uptake measurement. The medi-
an counts per minute from triplicate cultures are depicted as
percentage of the [3H]thymidine uptake detected in cells incubated
without IFN-a. (B) Psor-2 and Control-2 cells were cultured with IFN-a
(10,000 U per mL) for 24 h. Cells were then subjected to quantification
of apoptotic cells using the fluorescent DNA-binding dye, 7-amino-
actinomycin D. Mean fluorescence intensity (MFI) values from IFN-a-
stimulated cells are depicted as change in percent of MFI values
detected in cells incubated without IFN-a.
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an increased STAT–DNA binding, IFN-g production, and in-
hibition of T cell growth. Our finding that increased IFN-a
signaling is associated with psoriasis is in accordance with
a number of observations of psoriasis or exacerbated pso-
riasis in patients treated with IFN-a, i.e. IFN-a treatment of
viral infections (Yamamoto et al, 1995; Erkek et al, 2000),
viral hepatitis and myeloproliferative and lymphoprolifera-
tive disorders (Conlon et al, 1990; Funk et al, 1991; Pauluzzi
et al, 1993; Brenard, 1997; Calvino et al, 1999; Erkek et al,
2000). Moreover, Hida et al (2000) reported that the devel-
opment of a psoriasis-like inflammatory skin disease, be-
cause of lack of IRF-2 in IRF-2/ mice, was associated
with excessive IFN-a/b signaling, and that this signaling was
responsible for the development of the skin disease. By
investigating human psoriatic skin, van der Fits et al (2004)
recently demonstrated that the IFN-a/b signaling pathway
was indeed constitutively activated in psoriatic keratin-
ocytes. The sensitivity to IFN-a in these keratinocytes was,
however, not increased, and in contrast to IFN-g, IFN-a did
not directly induce a psoriatic phenotype on keratinocytes
(van der Fits et al, 2004). This suggests that the effect of
IFN-a in the pathogenesis of psoriasis might be indirect, and
thus might include other cell types involved in the stimula-
tion of keratinocyte hyperproliferation, such as T cells or NK
cells. Here, we demonstrate that psoriatic T cells have in-
creased responsiveness to IFN-a, suggesting that T cells
mediate the disease-promoting effect of IFN-a. In support
of this, CD8þ T cells were directly involved in the
pathogenetic process of the psoriasis-like skin disease in
IRF-2/ mice (Hida et al, 2000).
The observation by Hida et al (2000), that the develop-
ment of psoriasis-like inflammatory skin disease was de-
pendent on the signaling components IFNAR-1 and IRF-9,
suggests a selective involvement of the IFNAR/IFN-stimu-
lated gene factor 3 pathway. In accordance with this, our
findings on psoriatic T cells also included an increased IFN-
a-mediated STAT1 and STAT2 activation, which, together
with IRF-9, constitute the IFN-stimulated gene factor 3
complex. IFN-a-induced STAT3 activation has been linked
to T-Bet expression (Hibbert et al, 2003), and recent findings
on a constitutive activation of STAT3 in keratinocytes impli-
cated STAT3 in the pathogenesis of psoriasis (Sano et al,
2005). In agreement with these findings, we observed an
enhanced activation of STAT3 in psoriatic T cells. Interest-
ingly, we also found an increased IFN-a-mediated activation
of STAT4, suggesting that the involvement of IFN-a signaling
in human psoriasis includes other IFN-a-induced signaling
pathways. STAT4 is critically involved in the generation of
Th1 responses (Kaplan et al, 1996; Magram et al, 1996), and
has been shown to bind to the promotor of and thereby
regulate the IFN-g gene (Kaplan et al, 1996; Xu et al, 1996).
At the same time, IFN-a is known to upregulate type 1 im-
mune responses by enhancing differentiation and activation
of CD8þ T cells (Parronchi et al, 1996; Tough et al, 1996;
Sareneva et al, 1998, 2000), and to induce the development
of IFN-g-producing Th1 cells (Rogge et al, 1998), the latter
IFN-a-induced STAT4 of which is believed to play an im-
portant role. It is therefore conceivable to speculate that
increased sensitivity to IFN-a would induce increased IFN-g
production via STAT4. In this study, we show that increased
IFN-a-induced STAT4 activation in psoriatic T cells does in-
deed correlate with an increased DNA binding to the IFN-g
promotor, and an increased IFN-g production.
The IFN-a-induced signaling was shown to be increased
in psoriatic T cells even though a comparable amount of the
IFNAR was found on the surface of psoriatic and control T
cells, and comparable amounts of intracellular STAT pro-
teins were present in both cell types. At present, we are
unable to explain this increase in IFN-a sensitivity. The in-
creased IFN-a responsiveness in psoriatic T cells might re-
sult from a deficient expression or function of proteins
regulating the IFN-a signaling pathway. In a recent report
(Hida et al, 2000), excessive IFN-a/b signaling and the
spontaneous development of psoriasis-like inflammatory
skin disease were indeed found in mice lacking a transcrip-
tional attenuator of IFN-a/b signaling. In our study, the IFN-
a-induced STAT activation was increased in psoriatic T cells
already after 15 min. Our preliminary data suggest that
TYK2 activation is also increased in psoriasis. Studies are in
progress to address whether the enhanced STAT activation
is because of deficiencies in negative regulators, such as
tyrosine phosphatases like SH2 domain-containing protein
tyrosine phosphatase-1 (David et al, 1995) and suppressors
of cytokine signaling proteins (Alexander and Hilton, 2004;
Brender et al, 2005).
As a functional study of increased IFN-a response in
psoriatic T cells, we looked at the antiproliferative capacity
of IFN-a and measured the IFN-a-induced inhibition of IL-2-
mediated growth. Indeed, the inhibition of IL-2-mediated
growth by IFN-a was significantly stronger in psoriatic T
cells (Psor-2 cells) than in corresponding non-psoriatic
T cells (Control-2 cells) or T cells isolated from the blood
of healthy donors (alloreactive T cells) (Fig 7A, data not
shown). These results supported the conclusion above that
psoriatic T cells are more sensitive to IFN-a. IFN-a-induced
growth-arrested psoriatic T cells, however, did not correlate
with an increase in apoptosis (Fig 7B and data not shown).
In view of the actual in vivo situation in the local lesions of
psoriasis, one could therefore imagine that psoriatic T cells,
even under the influence of IFN-a, remain in the skin as
viable cells, able to perform their pathogenic function in
psoriatic plaques for a long period of time. Indeed, psoria-
sis–plaque xenografts on severe combined immunodefi-
ciency mice can be preserved for weeks to months and in
most cases continue to show the presence of viable T cells,
without the need for a continuing supply of fresh T cells from
the peripheral circulation (Wrone-Smith and Nickoloff, 1996;
Gilhar et al, 1997).
Altogether, these findings on an increased responsive-
ness of psoriatic T cells to IFN-a, which correlates with an
increased STAT–DNA binding to the IFN-g promotor and
IFN-g production, support and add to the proposed events
by Hida et al (2000) for an involvement of IFN-a in the
pathogenesis of psoriasis (Fig 8): (i) recruitment of CD8þ T
cells to the skin; (ii) hyper-responsiveness of these T cells to
IFN-a, because of a decreased control of the IFN-a signa-
ling; (iii) increased IFN-a-mediated responses, including the
production of IFN-g; and (iv) activation and proliferation of
other cell types, such as keratinocytes, which in turn would
further activate the T cells.
In conclusion, we provide evidence that T cells from
involved skin of psoriatic patients have an increased
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sensitivity to IFN-a. Thus, our data suggest that increased
IFN-a signaling is involved in the pathogenesis of psoriasis.
Materials and Methods
Antibodies and other reagents Recombinant human IFN-a
(Introna) was from Schering-Plough (Kenilworth, New Jersey).
Recombinant human IL-2 (Proleukin) was from Chiron (Emeryville,
California). Recombinant human IL-4 was from Leinco Technolo-
gies (St Louis, Missouri). Rabbit anti-human IFNAR-2 mAb was
from Research Diagnostics Inc. (Flanders, New Jersey). FITC-con-
jugated swine anti-rabbit polyclonal Ab (pAb) was from Dako
Cytomation (Glostrup, Denmark). FITC-conjugated mouse anti-hu-
man CD8 and CD3 mAb were from Leinco Technologies. PE-con-
jugated rat anti-human IL-2Rg mAb was from Becton Dickinson
Biosciences Pharmingen (San Jose, California). (The relevant iso-
type control Ab for the above Abs was used.) Phospho-specific
pAb against STAT1 (Tyr701) and STAT5 (Tyr694) was from Cell
Signaling Technology (Beverly, Massachusetts). Phospho-specific
STAT2 (Tyr689) pAb was from Upstate Biotechnology (Lake Placid,
New York). Phospho-specific STAT3 (Tyr704) mAb was from nano-
Tools (Denzlingen, Germany). Phospho-specific STAT4 (Tyr693)
pAb and mAb against STAT4 was from Zymed Laboratories (San
Francisco, California). STAT1 (E23), STAT2 (C-20), IFNAR-1 (R-100),
and ERK1/2 (K23) pAb were from Santa Cruz Biotechnology (Santa
Cruz, California). The ECL kit was from Amersham (Buckingham-
shire, UK). DNA-binding dye 7-amino-actinomycin D (7-AAD) was
from Sigma (St Louis, Missouri). The biotinylated double-stranded
oligonucleotide probe used for affinity purification was: Bio-IFN-g
(50-Bio-TCTGGTCATTTCCAAGAAAAGTTT-30), representing the
STAT4-binding sequence derived from the IFN-g-responsive pro-
motor of the IFN-g transcript (Xu et al, 1996). (The core STAT4-
recognition sequence is underlined.)
Subjects All subjects enrolled in this study have had no anti-
psoriatic treatment for 2 wk, and no systemic antipsoriatic treat-
ment for at least 4 wk prior to the obtainment of biopsies or blood
samples. Nor did they have any concurrent infections or medica-
tions. The enrollment of subjects and all experimental procedures
were carried out under protocols approved by the medical ethical
committees of each participating institution, and informed written
consent was obtained from all subjects. All experimental proce-
dures were conducted according to the Declaration of Helsinki
Principles.
T cell lines Biopsies taken from psoriasis patients were all taken
from the center of lesions with stable chronic plaques. The psoria-
tic cell lines, Psor-2 and -3, were continuous CD8þ /CD4/IF-
NARþ /CD25þ T cell lines established from punch biopsy
specimens of two different patients with psoriasis vulgaris as pre-
viously described (Kaltoft et al, 1995). The human CD8þ /CD4/
IFNARþ /CD25þ Tcell lines, Control-1, -2, and -3, are continuous T
cell lines derived from uninfected skin of three different patients
with diseases other than psoriasis as described in detail elsewhere
(Kaltoft et al, 1992, 1994). Allo-reactive human CD8þ /CD4þ /IF-
NARþ /CD25þ T cell lines were obtained from healthy individuals
and have previously been described (Nielsen et al, 1994). The hu-
man T cell lines, CD8/CD4þ /IFNARþ /CD25þ Psor-16 and -17,
and Psor-18 and -19, from two different psoriasis patients were
established from T cells migrated from biopsy fragments grown in
culture for a few weeks as described previously (Skov et al, 1997).
The different psoriasis T cell lines do primarily have a Th1-cytokine
profile (Nielsen et al, 1998, data not shown), and all cells from both
control and psoriasis patients respond equally well to growth fac-
tors such as IL-2, IL-4, IL-7, and IL-15. Cells were cultured in RPMI
1640 (Sigma) supplemented with 2 mM L-glutamine, 100 mg per mL
penicillin, 100 mg per mL streptomycin (Sigma), 10% pooled human
serum, 1000 U per mL IL-2, and 10 ng per mL IL-4. Cells were
washed twice and starved for IL-2 and IL-4 for 16–18 h before
initiation of the experiments described below.
Isolation of PBL Blood from three different psoriasis patients and
three different healthy control donors was individually subjected to
density gradient centrifugation using Lymphoprep (Axis-Shield
PoC AS, Oslo, Norway). PBL were subsequently isolated, washed
three times in pre-warmed phosphate-buffered saline, and resus-
pended and left in culture medium (see description above) without
cytokines for 4 h, prior to FACS analysis and western blotting as
described below. FACS analysis of psoriasis and control PBL re-
vealed a comparable amount of IFNARþ and CD3þ cells, and that
around 70% of the cells were CD3þ .
Protein extraction, oligonucleotide afﬁnity puriﬁcation of STAT
proteins, and western blotting After stimulation with or without
IFN-a for the indicated times, the cells (1.5  106 cells/experiment
for whole-cell lysates and 20  106 cells/experiment for oligonuc-
leotide affinity purification) were rapidly pelleted and lysed in ice-
cold lysis buffer as described previously (Eriksen et al, 2004). The
oligonucleotide affinity purification and the western blotting pro-
cedure are described in detail elsewhere (Eriksen et al, 2001). Blots
were evaluated using ECL, stripped, and reprobed according to
the manufacturer’s manual (Amersham).
FACS analysis of cell surface expression Cells were harvested
(5  105), washed three times in washing buffer (PBS, 5% fetal calf
serum, 0.1% sodium azide), and pelleted. The cells were resus-
pended in 4 mL labeled Ab, vortexed, and incubated for 30 min at
41C in the dark. The cells were washed three times in washing
buffer and stored at 41C in the dark until they were analyzed on
FACScan (Becton Dickinson, Franklin Lakes, New Jersey). 104
cells per sample were analyzed.
ELISA Cells were cultured at 2.0  103 cells per well in 12-well
plates for 24 h with or without IFN-a in a final volume of 800 mL. The
IFN-g production was analyzed by sandwich ELISA according
to the manufacturer’s protocol (Becton Dickinson Biosciences
Pharmingen).
Figure 8
Hypothetical pathogenic involvement of interferon (IFN)-a in
psoriatic plaques. 1., Infiltrating CD8þ T cells in the epidermis are
hyper-responsive to IFN-a, because of decreased control of the IFN-a
signaling. 2., Increased IFN-a-mediated responses includes the pro-
duction of IFN-g. 3., IFN-g triggers the maturation and activation of
dendritic cells, and the activation and hyperproliferation of keratin-
ocytes. The subsequent expression of growth factors, chemokines,
adhesion molecules, and inflammatory mediators by dendritic cells and
keratinocytes ensures a persistent infiltration of leukocytes, which
eventually maintains the chronic psoriatic lesion (Lew et al, 2004) (DC,
dendritic cells).
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Proliferation assay Assays were performed in culture medium
(RPMI 1640) supplemented with 10% human serum, 2 mM L-
glutamine, 100 mg per mL penicillin, 100 mg per mL streptomycin,
and 1000 U per mL IL-2 in 96-well round-bottomed tissue culture
plates (Nunc, Roskilde, Denmark) with a final volume of 200 mL.
Psor-2, Control-2, and alloreactive T cells were cultured at
25  103 cells per well for 24, 48, 72, or 96 h with or without
reagents as indicated. Twelve hours before harvest, [3H]thymidine
(Amersham) (1 mCi per well; 1 Ci¼ 37 GBq) was added. The cells
were harvested onto glass fiber filters, [3H]thymidine incorporation
was measured in a scintillation counter, and the results were ex-
pressed as median counts per minute from triplicate cultures.
Quantiﬁcation of apoptotic cells Apoptotic cells were quantified
by the use of the DNA-binding dye 7-AAD as described in detail
(Sommer et al, 2004). Cells were harvested (5  105), washed three
times in washing buffer (PBS, 5% fetal calf serum, 0.1% sodium
azide), resuspended in 0.5 mL 0.05% saponin in PBS, and pellet-
ed. The cells were resuspended in 0.5 mL 4 mg per mL 7-AAD in
0.05% saponin in PBS, incubated at room temperature in the dark
in 30–45 min, and analyzed on FACScan. Untreated cells were
used to set gates for viable cells with 2–4N DNA, for apoptotic cells
with subnormal DNA content, and for exclusion of debris.
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